Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,932
datasets available to search
ShareScore release 0.9.0
Dataset results
1,932 results for “Metformin”
Mechanisms of Glucose Lowering Effects of Sitagliptin and Metformin Alone and in Combination in Patients With T2DM
ClinicalTrials.gov study NCT00820573. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin
ClinicalTrials.gov study NCT02429258. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Data associated with 'Metformin rescues Parkinson's disease phenotypes caused by hyperactive mitochondria'
<p>Metabolic dysfunction occurs in many age-related neurodegenerative diseases, yet its role in disease etiology remains poorly understood. We recently discovered a potential causal link between the branched-chain amino acid transferase, <i>BCAT-1,</i> and the neurodegenerative movement disorder, Parkinson's disease (PD). RNAi-mediated knockdown of <i>C. elegans bcat-1</i> recapitulates PD-like features, including progressive motor deficits and neurodegeneration with age, yet the underlying mechanisms have remained unknown. Using transcriptomic, metabolomic, and imaging approaches, we show here that <i>bcat-1 </i>knockdown increases mitochondrial respiration and induces oxidative damage in neurons through mTOR-independent mechanisms. Increased mitochondrial respiration, or 'mitochondrial hyperactivity,' is required for <i>bcat-1(RNAi)</i> neurotoxicity. Moreover, we show that post-disease onset administration of the type 2 diabetes medication, metformin, reduces mitochondrial respiration to control levels and significantly improves both motor function and neuronal viability. Together, our findings suggest that mitochondrial hyperactivity may be an early event in PD pathogenesis, and strategies aimed at reducing mitochondrial respiration may constitute a surprising new avenue for PD treatment.</p>
Gut microbiota-derived gamma-aminobutyric acid from metformin treatment reduces hepatic ischemia/reperfusion injury by inhibiting ferroptosis
<div>Hepatic ischemia/reperfusion injury (HIRI) is a common and inevitable factor leading to poor prognosis in various liver diseases, making the outcomes of current treatments in the clinic unsatisfactory. Metformin has been demonstrated to be beneficial in alleviating HIRI in recent studies, however, the underpinning mechanism remains unclear. In this study, we found metformin mitigates HIRI-induced ferroptosis through reshaped gut microbiota in mice, which was confirmed by the results of fecal microbiota transplantation treatment but showed the elimination of the beneficial effects when gut bacteria were depleted using antibiotics. Detailedly, through 16S rRNA and metagenomic sequencing, we identified that the metformin-reshaped microbiota was characterized by the increase of gamma-aminobutyric acid (GABA) producing bacteria. This increase was further confirmed by the elevation of GABA synthesis key enzymes, glutamic acid decarboxylase, and putrescine aminotransferase, in gut microbes of metformin-treated mice and healthy volunteers. Furthermore, the benefit of GABA against HIRI-induced ferroptosis was demonstrated in GABA-treated mice. Collectively, our data indicate that metformin can mitigate HIRI-induced ferroptosis by reshaping gut microbiota, with GABA identified as a key metabolite.</div>
Effect of acupuncture and metformin on insulin sensitivity in women with polycystic ovary syndrome and insulin resistance: a three-armed randomized controlled trial
<p>STUDY QUESTION</p> <p>Does acupuncture improve insulin sensitivity more effectively than metformin or sham acupuncture in women with polycystic ovary syndrome (PCOS) and insulin resistance (IR)?</p> <p>SUMMARY ANSWER</p> <p>Among women with PCOS and IR, acupuncture was not more effective than metformin or sham acupuncture in improving insulin sensitivity.</p> <p>WHAT IS KNOWN ALREADY</p> <p>Uncontrolled trials have shown that acupuncture improved insulin sensitivity with fewer side effects compared with metformin in women with PCOS and IR. However, data from randomized trials between acupuncture and metformin or sham acupuncture are lacking.</p> <p>STUDY DESIGN, SIZE, DURATION</p> <p>This was a three-armed randomized controlled trial enrolling a total of 342 women with PCOS and IR from three hospitals between November 2015 and February 2018, with a 3-month follow-up until October 2018.</p> <p>PARTICIPANTS/MATERIALS, SETTING, METHODS</p> <p>Women aged from 18 to 40 years with PCOS and homeostasis model assessment of insulin resistance (HOMA-IR) ≥2.14 were randomly assigned (n = 114 per group) to receive true acupuncture plus placebo (true acupuncture), metformin plus sham acupuncture (metformin, 0.5 g three times daily) or sham acupuncture plus placebo (sham acupuncture) for 4 months, with an additional 3-month follow-up. True or sham acupuncture was given three times per week, and 0.5 g metformin or placebo was given three times daily. The primary outcome was change in HOMA-IR from baseline to 4 months after baseline visit. Secondary outcomes included changes in the glucose AUC during an oral glucose tolerance test, BMI and side effects at 4 months after baseline visit.</p> <p>MAIN RESULTS AND THE ROLE OF CHANCE</p> <p>After 4 months of treatment, the changes of HOMA-IR were –0.5 (decreased 14.7%) in the true acupuncture group, –1.0 (decreased 25.0%) in the metformin group and –0.3 (decreased 8.6%) in the sham acupuncture group, when compared with baseline. True acupuncture is not as effective as metformin in improving HOMA-IR at 4 months after baseline visit (difference, 0.6; 95% CI, 0.1–1.1). No significant difference was found in change in HOMA-IR between true and sham acupuncture groups at 4 months after baseline visit (difference, –0.2; 95% CI, –0.7 to 0.3). During the 4 months of treatment, gastrointestinal side effects were more frequent in the metformin group, including diarrhea, nausea, loss of appetite, fatigue, vomiting and stomach discomfort (31.6%, 13.2%, 11.4%, 8.8%, 14.0% and 8.8%, respectively). Bruising was more common in the true acupuncture group (14.9%).</p> <p>LIMITATIONS, REASONS FOR CAUTION</p> <p>This study might have underestimated the sample size in the true acupuncture group with 4 months of treatment to enable detection of statistically significant changes in HOMA-IR with fixed acupuncture (i.e. a non-personalized protocol). Participants who withdrew because of pregnancy did not have further blood tests and this can introduce bias.</p> <p>WIDER IMPLICATIONS OF THE FINDINGS</p> <p>True acupuncture did not improve insulin sensitivity as effectively as metformin in women with PCOS and IR, but it is better than metformin in improving glucose metabolism (which might reduce the risk of type 2 diabetes) and has less side effects. Metformin had a higher incidence of gastrointestinal adverse effects than acupuncture groups, and thus acupuncture might be a non-pharmacological treatment with low risk for women with PCOS. Further studies are needed to evaluate the effect of acupuncture combined with metformin on insulin sensitivity in these women.</p> <p>STUDY FUNDING/COMPETING INTEREST(S)</p> <p>This work was supported by grants 2017A020213004 and 2014A020221060 from the Science and Technology Planning Project of Guangdong Province. The authors have no conflicts of interest.</p> <p>TRIAL REGISTRATION NUMBER</p> <p>Clinicaltrials.gov number: NCT02491333.</p> <p>TRIAL REGISTRATION DATE</p> <p>8 July 2015.</p> <p>DATE OF FIRST PATIENT'S ENROLLMENT</p> <p>11 November 2015.</p>
Comparative Efficacy and Safety of Sitagliptin Phosphate Combined with Gliclazide Sustained-Release Tablets Versus Metformin in Treatment-Naïve Patients with Type 2 Diabetes Mellitus and Glucotoxicity: A Single-Center, Prospective, Randomized Controlled Non-Inferiority Study
<p>This dataset supports the manuscript titled "Comparative Efficacy and Safety of Sitagliptin Phosphate Combined with Gliclazide Sustained-Release Tablets Versus Metformin in Treatment-Naïve Patients with Type 2 Diabetes Mellitus and Glucotoxicity: A Single-Center, Prospective, Randomized Controlled Non-Inferiority Study." The study aims to compare the efficacy and safety of sitagliptin phosphate combined with gliclazide sustained-release tablets against metformin in treatment-naïve patients with type 2 diabetes mellitus and glucotoxicity. Data include clinical measurements, laboratory test results, and adverse event records collected throughout the trial period. Statistical analyses were conducted to assess non-inferiority between the two treatment groups. This dataset provides valuable insights for researchers interested in diabetes management, pharmacotherapy, and randomized controlled trials.</p>
Emp vs metformin in HF
<p>data set in excel file</p>
Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes
ClinicalTrials.gov study NCT06759922. IPD Sharing: YES. Countries: 1. Publications: 14.
A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)
ClinicalTrials.gov study NCT01709305. IPD Sharing: YES. Countries: 0. Publications: 1.
Short Term Weight Loss With Liraglutide and Metformin in Infertile Obese PCOS Patients
ClinicalTrials.gov study NCT03034941. IPD Sharing: YES. Countries: 1. Publications: 3.
Metformin And Chloroquine in IDH1/2-mutated Solid Tumors
ClinicalTrials.gov study NCT02496741. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer
ClinicalTrials.gov study NCT03379909. IPD Sharing: NO. Countries: 1. Publications: 1.
Metformin Immunotherapy in HIV Infection
ClinicalTrials.gov study NCT02659306. IPD Sharing: Not stated. Countries: 1. Publications: 5.
Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease)
ClinicalTrials.gov study NCT05532813. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
ClinicalTrials.gov study NCT04850846. IPD Sharing: YES. Countries: 1. Publications: 0.
The Effects of Metformin on Self-selected Exercise Intensity, Physical Fitness and Exercise-induced AMPK-activation
ClinicalTrials.gov study NCT02951260. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Metformin+ Drospirenone/ethinylestradiol30µg and Flow-mediated Dilation in Polycystic Ovary Syndrome
ClinicalTrials.gov study NCT01459445. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Metformin in Children With Fragile X Syndrome
ClinicalTrials.gov study NCT05120505. IPD Sharing: NO. Countries: 1. Publications: 1.
Metformin Treatment on Cognitive Impairment of Schizophrenia Co-morbid Metabolic Syndrome
ClinicalTrials.gov study NCT03271866. IPD Sharing: Not stated. Countries: 1. Publications: 5.
Comparison of Metformin and Pioglitazone Effects on Adipokines Concentrations in Newly Diagnosed Type 2 Diabetes Patients
ClinicalTrials.gov study NCT01593371. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.